The drug reduced prolactin levels, irrespective of the reason for prolactin excess, including in individuals with iatrogenic hyperprolactinemia [3,4,5,6], prolactin-secreting tumors [7], hyperprolactinemia secondary to traumatic brain injury [7] and prolactin excess related to empty sella syndrome [7], as well as in idiopathic hyperprolactinemia [7]. Here, PRL is linked to empty sella syndrome.